ISRCTN85124072 https://doi.org/10.1186/ISRCTN85124072

Oral versus vaginal misoprostol for medical management of early foetal demise

Submission date	Recruitment status	[ ] Prospectively registered
26/02/2009	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
21/04/2009	Completed	[X] Results
Last Edited	**Condition category**	[ ] Individual participant data
24/10/2019	Pregnancy and Childbirth	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Elaine Gouk

Contact details
University Hospital of North Tees
Hardwick Road
Stockton-on-Tees, Cleveland
United Kingdom
TS19 8PE

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
A randomised controlled trial of oral versus vaginal misoprostol for medical management of early foetal demise

Study objectives

When used in conjunction with oral mifepristone (200 mg), a single dose of vaginal misoprostol (800 micrograms) has a higher success rate in treating early foetal demise than an oral regimen of misoprostol (600/400/400 micrograms).

Ethics approval required
Old ethics approval format

Ethics approval(s)
South Tees Hospital Trust Ethics Committee, 23/09/1997, ref: 97/69

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Medical management of miscarriage

Interventions
In both groups, oral mifeprostone (200 mg) was given and then the misoprotol administered 48 hours later. The vaginal regimen was given once only. If no products were passed/seen, even on vaginal speculum examination, this could be repeated the next day. The oral regime (600/400 /400 micrograms) was given at two hourly intervals. Again, if the miscarriage had not completed, this could be reviewed the next day.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Mifepristone, misoprostol

Primary outcome(s)
Clinically diagnosed completion of miscarriage

Key secondary outcome(s))
1. Parity, assessed at initial presentation
2. Anembryonic/embryonic early foetal demise assessed at time of ultrasound scan and miscarriage diagnosis
3. Side effects (pain, diarrhoea, vomiting), assessed during treatment and inpatient stay
4. Analgesia use

Completion date
30/12/2000

Eligibility

Key inclusion criteria
Women with an ultrasound diagnosis of (singleton) early foetal demise, with no medical contraindications or known allergy to misoprostol or mifepristone.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
Female

Key exclusion criteria
1. Heavy smokers (of >20 cigarettes day)
2. Aged >35 years
3. Severe asthma
4. Cardiovascular disease, hypertension (blood pressure [BP] >160/100 mmHg)
5. Chronic adrenal, renal or hepatic failure
6. Porphyria or haemorrhagic disorders
7. Long term corticosteroid
8. Anticoagulant or non-steroidal anti-inflammatory drug (NSAID) therapy
9. Known allergy to mifepristone or misoprostol

Date of first enrolment
01/01/1997

Date of final enrolment
30/12/2000

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
University Hospital of North Tees
Stockton-on-Tees, Cleveland
United Kingdom
TS19 8PE

Sponsor information

Organisation
South Tees Hospitals NHS Trust (UK)

ROR
https://ror.org/02js17r36

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
The James Cook University Hospital (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2009	24/10/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes